Related references
Note: Only part of the references are listed.Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Farzin Khosrow-Khavar et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
Andra-Rodica Balanescu et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Cardiovascular effects of approved drugs for rheumatoid arthritis
Fabiola Atzeni et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Siddharth Singh et al.
ARTHRITIS CARE & RESEARCH (2020)
Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
Jon T. Giles et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
Philip Mease et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Donna K. Arnett et al.
CIRCULATION (2019)
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
Christina Charles-Schoeman et al.
ARTHRITIS & RHEUMATOLOGY (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
Scott M. Grundy et al.
CIRCULATION (2019)
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis A Randomized Clinical Trial
Daniel H. Solomon et al.
ARTHRITIS & RHEUMATOLOGY (2018)
EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update
R. Agca et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Effect of TNF alpha-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Michael Sattin et al.
CURRENT RHEUMATOLOGY REVIEWS (2016)
Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
Christina Charles-Schoeman et al.
ARTHRITIS & RHEUMATOLOGY (2015)
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis
Jie Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
David C. Goff et al.
CIRCULATION (2014)
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment
Ernest Choy et al.
RHEUMATOLOGY (2014)
Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
Juan Antonio Avina-Zubieta et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
George D. Kitas et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
A Review of Quantitative Risk-Benefit Methodologies for Assessing Drug Safety and Efficacy-Report of the ISPOR Risk-Benefit Management Working Group
Jeff J. Guo et al.
VALUE IN HEALTH (2010)
Share Paper
